Literature DB >> 16094412

Compliance of sildenafil treatment for erectile dysfunction and factors affecting it.

B-P Jiann1, C-C Yu, C-C Su, J-Y Tsai.   

Abstract

To assess the compliance of treatment, its affecting factors, and reasons for dropout, a questionnaire was mailed to a cohort of 2139 subjects who received sildenafil prescriptions for erectile dysfunction (ED) at our institution from 1999 to 2002. A total of 726 subjects (34%) with a mean age of 67 years answered the questionnaires. The response rate for sildenafil treatment was 67%. Of these sildenafil responders, 43% reported that they continued using sildenafil while 57% did not, in a mean follow-up of 3 years. Common reasons for discontinuation were effect below expectations, high cost, loss of interest in sex, and inconvenience in obtaining sildenafil. The continuers showed a higher rate than the discontinuers (P < 0.05) of having tried other treatments, dose titration, and a dose higher than 50 mg. The discontinuers reported having a lower mean responding dose and improvement score post sildenafil treatment than the continuers. In conclusion, effect below expectations was the leading reason for discontinuation of sildenafil treatment. How ED subjects tried the medication and the adequacy of education in the initial treatment period may impact the compliance of sildenafil treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16094412     DOI: 10.1038/sj.ijir.3901379

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  17 in total

Review 1.  Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience.

Authors:  Béatrice Cuzin
Journal:  Ther Adv Urol       Date:  2016-05-03

2.  Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.

Authors:  W-K Tsai; B-P Jiann
Journal:  Int J Impot Res       Date:  2014-01-23       Impact factor: 2.896

Review 3.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

4.  Results from an online survey investigating ED patients' insights and treatment expectations.

Authors:  A Burri; H Porst
Journal:  Int J Impot Res       Date:  2015-07-30       Impact factor: 2.896

Review 5.  Erectile dysfunction.

Authors:  Faysal A Yafi; Lawrence Jenkins; Maarten Albersen; Giovanni Corona; Andrea M Isidori; Shari Goldfarb; Mario Maggi; Christian J Nelson; Sharon Parish; Andrea Salonia; Ronny Tan; John P Mulhall; Wayne J G Hellstrom
Journal:  Nat Rev Dis Primers       Date:  2016-02-04       Impact factor: 52.329

6.  A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients.

Authors:  A Natali; L Masieri; M Lanciotti; S Giancane; G Vignolini; M Carini; S Serni
Journal:  Int J Impot Res       Date:  2014-07-24       Impact factor: 2.896

Review 7.  Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.

Authors:  Paul Williams; Hayley McBain; Aliya Amirova; Stanton Newman; Kathleen Mulligan
Journal:  Int J Impot Res       Date:  2020-03-31       Impact factor: 2.896

8.  Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.

Authors:  Konstantinos Giannitsas; Angelis Konstantinopoulos; Christos Patsialas; Petros Perimenis
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients.

Authors:  S-C Kim; Y-S Lee; K-K Seo; G-W Jung; T-H Kim
Journal:  Int J Impot Res       Date:  2013-12-05       Impact factor: 2.896

10.  Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mg.

Authors:  John P Mulhall; Dana L Creanga; Vera J Stecher
Journal:  Int J Gen Med       Date:  2013-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.